Anti-CDR2 antibody
| 英文名称 | CDR2 |
| 中文名称 | 小脑变性相关蛋白2抗体 |
| 别 名 | CDR 2; CDR 62; CDR2; CDR2_HUMAN; CDR62; Cerebellar degeneration related protein 2; Cerebellar degeneration related protein; Cerebellar degeneration-related protein 2; Major Yo paraneoplastic antigen; Paraneoplastic cerebellar degeneration associated antigen; Paraneoplastic cerebellar degeneration-associated antigen; PCD 17; PCD17; Yo antibody; Yo paraneoplastic antigen. |
DATASHEET
Host:Rabbit
Target Protein:CDR2
IR:Immunogen Range:381-454/454
Clonality:Polyclonal
Isotype:IgG
Entrez Gene:1039
Swiss Prot:Q01850
Source:KLH conjugated synthetic peptide derived from human CDR2/PCD17:381-454/454
Purification:affinity purified by Protein A
Storage:0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles.
Background:CDR2 (cerebellar degeneration-related protein 2), also referred to as Yo or CDR62, is a 545 amino acid protein that is associated with the development of paraneoplastic cerebellar degeneration (PCD). PCD, an immune-mediated syndrome, belongs to a heterogeneous group of rare paraneoplastic neurologic disorders affecting the neurological system. PCD is characterized by subacute cerebellar ataxia and occurs mainly in patients with ovarian, uterine, fallopian tube or breast cancer. Patients with ovarian or breast cancer develop an immune response against cancer cell-expressed CDR2 and Purkinje neuron-expressed CDR2. The presence of the anti-CDR2 antibody in patients with PCD symptoms warrants an aggressive approach to diagnosis and treatment of the underlying cancer.
好评度